{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD+%28Inflammatory+Bowel+Disease%29", "query": { "condition": "IBD (Inflammatory Bowel Disease)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1192, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD+%28Inflammatory+Bowel+Disease%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T13:17:46.566Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00063414", "title": "ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Alicaforsen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-11-20", "completion_date": "2005-03-24", "has_results": false, "last_update_posted_date": "2022-12-05", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063414" }, { "nct_id": "NCT03395184", "title": "Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "PF-06651600 Placebo", "type": "DRUG" }, { "name": "PF-06651600", "type": "DRUG" }, { "name": "Placebo PF-06700841", "type": "DRUG" }, { "name": "PF-06700841", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 244, "start_date": "2018-02-02", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 57, "location_summary": "Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03395184" }, { "nct_id": "NCT07356232", "title": "Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Crohn's Disease, Active" ], "interventions": [ { "name": "Partial enteral nutrition - orally consumed formula", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2026-04", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07356232" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT04431700", "title": "Study of Dietary Composition in Crohn's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Diseases", "Crohn Disease" ], "interventions": [ { "name": "Anti-inflammatory diet", "type": "OTHER" }, { "name": "Regular diet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2020-10-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04431700" }, { "nct_id": "NCT06794944", "title": "Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Inflammatory Bowel Disease (IBD)", "Clostridioides Difficile Infection" ], "interventions": [ { "name": "Vancomycin (POC)", "type": "DRUG" }, { "name": "Fidaxomicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-09", "completion_date": "2031-09", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06794944" }, { "nct_id": "NCT02460705", "title": "Fecal Microbiota Transplant for Inflammatory Bowel Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Inflammatory Bowel Disease" ], "interventions": [ { "name": "Biologically active human fecal material, OpenBiome", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2015-06", "completion_date": "2017-11-04", "has_results": false, "last_update_posted_date": "2018-06-21", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02460705" }, { "nct_id": "NCT07071519", "title": "A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Risankizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 120, "start_date": "2025-07-28", "completion_date": "2034-07", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 11, "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07071519" }, { "nct_id": "NCT02322307", "title": "Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammatory Bowel Disease", "Crohn's Disease", "Ulcerative Colitis" ], "interventions": [ { "name": "HealthPROMISE users", "type": "OTHER" }, { "name": "Control Group", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2015-02", "completion_date": "2020-01-20", "has_results": false, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02322307" }, { "nct_id": "NCT02425111", "title": "Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 101, "start_date": "2015-03-30", "completion_date": "2018-02-21", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-06-10T13:17:46.566Z", "location_count": 22, "location_summary": "La Jolla, California • Hamden, Connecticut • Gainesville, Florida + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Inverness", "state": "Florida" }, { "city": "Maitland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02425111" } ] }